Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.
They successfully edited the gene in mice in vivo and their approach could also work for a range of heterozygous disease-causing SNPs.
Exome sequencing poorly covers some known disease genes, but identifies novel genes that that Harvard team thinks will help improve panel's diagnostic rate.
The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.
Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.
Some science companies will be taking part in next month's March for Science, Fortune reports.
In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.
Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.